ClinicalTrials.gg
TerminatedNCT05584137Updated Oct 15, 2024

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

A Phase 2 interventional study of HLX26 and HLX10 in Colorectal Cancer Metastatic, sponsored by Shanghai Henlius Biotech. Terminated at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to poor clinical trial accrual, the study was terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing serplulimab in Colorectal Neoplasms — 12 open to participants now, 12 under way, 2 of them phase 3. serplulimab · Colorectal Neoplasms.

Enrollment
13th of 13
2 · median 51
Started
2023
with 3 others
Phase 2
10 of 13
9 open now
Registered
2nd of 13
by date
Lead sponsor
2 of 13
Shanghai Henlius Biotech

Among the 13 studies testing serplulimab in Colorectal Neoplasms, this one is the 13th largest by enrollment, is one of 4 that started in 2023, is one of 10 in phase 2, and was the 2nd registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 13 studies testing serplulimab in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing serplulimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.

Read the detailed description

This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.

The study is composed of the first stage (escalation stage) and the second stage (expansion stage). In the first stage (escalation stage), a 3 + 3 dose escalation design will be used. Patients will receive 3 dose levels of HLX26 (500mg, 800mg, 1600mg) combined with HLX10 300mg intravenously every 3 weeks. Observation period of DLT lasts for 3 weeks after the first administration of HLX26. In the second stage, the safety and efficacy of 2 dose levels of HLX26 (800mg and 1600mg) combined with HLX10 300mg will be evaluated. Eligible subjects will be enrolled in the HLX26 800mg group and HLX26 1600mg group in sequence, 20 subjects per group.

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed colorectal adenocarcinoma that is and unresectable.
  • Has at least one per 1.1 as assessed by investigator.
  • Has been treated with 3 for the disease and radiographically progressed on or after or could not tolerate prior therapies which include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, an anti-EGFR therapy (if KRAS wild-type), regorafenib, TAS-102, fruquintinib, and BRAF inhibitor (if BRAF mutant-type).
  • Submits an archival (≤ 5 years) or newly obtained tumor tissue sample that has not been previously irradiated for the determination of level and mismatch repair (MMR) status to meet the study requirements.
  • Has an Performance Score (ECOG PS) of 0 to 1 within 7 days prior to first dose of study intervention.
  • Has a of at least 3 months, based on the investigator assessment.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has previously been found to have deficient MMR/microsatellite instability-high (dMMR/MSI-H) tumor status.
  • The adverse reactions (except alopecia and other adverse reactions determined by the investigator to have no safety risk) of previous anti-tumor therapy have not yet recovered to ≤ grade 1 ( V5.0).
  • Those who are known to have severe anaphylaxis (grade 4 or greater per CTCAE V5.0) to macromolecular protein preparations/monoclonal antibodies or to any component of the product.
  • Patients with any of the following unstable or poorly controlled diseases:1)Active systemic infectious diseases requiring intravenous antibiotics within 2 weeks prior to the first administration of the investigational product;2)Any poorly-controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited to: (a) Class II or greater cardiac failure or (LVEF) \< 50%; (b) unstable angina pectoris; (c) myocardial infarction and cerebral infarction within 6 months; (d) supraventricular or ventricular arrhythmia that has not been intervened or is poorly controlled after clinical intervention; 3)Other chronic diseases which, in the opinion of the investigator, may compromise the safety of the patient or the integrity of the study.
  • Assessed as unsuitable for inclusion by the investigator, due to , spinal cord compression, or cancerous meningitis with clinical symptoms, or uncontrolled brain or spinal cord that have been evidenced.
  • Previous grade 2 or greater immune pneumonia in immunotherapy; previous grade 3 or greater irAEs in immunotherapy.
  • Has had other malignant tumors within 5 years before enrollment, except: (a) those with cured cervical carcinoma in situ or non-melanoma skin cancer; (b) those with cured second primary cancer without recurrence within 5 years; (c) those with double primary cancers believed to be able to benefit from this study; (d) those whose metastasis has been clearly excluded from a certain primary tumor source.
  • History of prior treatment with /L1, anti-CTLA-4, anti-Lag-3 antibodies or any agent targeting T cells.
  • Has active diseases (including but not limited to the following diseases or syndromes, such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism), except: vitiligo or cured childhood asthma/allergy that does not need any intervention in adulthood, autoimmune mediated hypothyroidism treated with stable dose of thyroid replacement hormone, and type I diabetes treated with stable dose of insulin; those in a stable condition and requiring no systemic therapy (including hormone) are allowed to be enrolled.
  • Has received systemic corticosteroids (prednisone > 10 mg/d or equivalent dose of similar drug) or other immunosuppressants within 14 days before the first administration; Except: patients treated with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; those with short term use of corticosteroids for prophylaxis, such as contrast agents.
  • Patients in pregnancy [confirmed by serum beta-human chorionic gonadotropin (ß-HCG) test] or breastfeeding.
  • Has a history of immunodeficiency, including (HIV)-positive or other acquired or congenital immunodeficiencies, or a history of organ transplantation.
  • Patients with active or infection (HBV DNA ≥ 10*4 copies/mL or positive HCV RNA, but patients with HBV DNA \< 10*4 copies / mL after treatment can be included); Subjects with co-infection of hepatitis B and hepatitis C (HBsAg or HBcAb positive, and HCV antibody positive).
  • Has received within 28 days prior to the first administration.
  • Patients whose medical history or any other evidence suggests that participation in the study may confuse the results, or subjects for whom the investigator believes the study is not in their best interest.
  • Participating in other clinical studies or less than 28 days from the end of the treatment of the previous clinical study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Dose cohort 1 of the first stage (escalation stage)

    In this cohort, HLX26 500 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). Interventions: Drug: HLX26 Drug: HLX10

    Drug: HLX26 · Drug: HLX10

  • Experimental
    Dose cohort 2 of the first stage (escalation stage)

    In this cohort, HLX26 800 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). Interventions: Drug: HLX26 Drug: HLX10

    Drug: HLX26 · Drug: HLX10

  • Experimental
    Dose cohort 3 of the first stage (escalation stage)

    In this cohort, HLX26 1600 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 3 to 6 subjects will be enrolled in this cohort. 3 to 6 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). Interventions: Drug: HLX26 Drug: HLX10

    Drug: HLX26 · Drug: HLX10

  • Experimental
    Dose cohort 1 of the second stage (expansion stage)

    In this cohort, HLX26 800 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 20 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). Interventions: Drug: HLX26 Drug: HLX10

    Drug: HLX26 · Drug: HLX10

  • Experimental
    Dose cohort 2 of the second stage (expansion stage)

    In this cohort, HLX26 1600 mg in combination with HLX10 300 mg will be intravenously administered every 3 weeks. 20 subjects will be enrolled in this cohort. Patients will be treated with investigational products until 2 years, disease progression, death, receiving new antitumor treatment, intolerable toxicity or withdrawal of informed consent (whichever occurs first). Interventions: Drug: HLX26 Drug: HLX10

    Drug: HLX26 · Drug: HLX10

Interventions

  • DrugHLX26

    Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

    Also known as: Anti-LAG-3 Monoclonal Antibody

  • DrugHLX10

    Humanized Anti-Programmed Death-1 Monoclonal Antibody

    Also known as: Anti-PD-1 Humanized Monoclonal Antibody, SERPLULIMAB

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) (the first stage)

    The DLT of HLX26 in combination with HLX10 within 3 weeks after the first administration in patients with metastatic colorectal carcinoma.

    Time frame: from day1 to day 21

  2. Maximum Tolerated Dose (MTD) (the first stage)

    The MTD of HLX26 in combination with HLX10 within 3 weeks after the first administration in patients with metastatic colorectal carcinoma.

    Time frame: from day1 to day 21

  3. Objective Response Rate (ORR) per RECIST 1.1 as Assessed by Investigator (the second stage)

    The ORR is defined as the percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by investigator.

    Time frame: approximately up to 6 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from first dose to death due to any cause.

    Time frame: approximately up to 24 months

  2. Progression-Free Survival (PFS) per RECIST 1.1 assessed by Investigator

    PFS is defined as the time from first dose to the first documented disease progression per RECIST 1.1 by investigator or death due to any cause, whichever occurs first.

    Time frame: approximately up to 24 months

  3. Duration of Response (DOR) per RECIST 1.1 assessed by Investigator

    DOR is defined as the time from the first documented CR or PR until disease progression or death due to any cause, whichever occurs first. DOR is only for participants who demonstrate confirmed ORR.

    Time frame: approximately up to 6 months

07

Study locations

2 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Dec 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 18, 2022
StartActual
Jun 15, 2023
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05584137
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Jun 15, 2023
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
Oct 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-LAG-3 Monoclonal Antibody HLX26 · Serplulimab

Start the discussion